Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons. The Trump ...

New York, New York-- (Newsfile Corp. - April 1, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, ...

Discover the latest April 2025 update on Dow Dogs! Learn about top investment picks, forecasted gains, and market corrections ...

Learn more about whether Jazz Pharmaceuticals plc or Merck & Co., Inc. is a better investment based on AAII's A+ Investor ...

Learn more about whether Corcept Therapeutics Incorporated or Merck & Co., Inc. is a better investment based on AAII's A+ ...

Merck & Co has announced the first presentation of full results from the Phase III ZENITH trial of Winrevair ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET ...

Merck dazzled with Phase 3 trial results for its PAH drug WINREVAIR, but the market responded with a collective shrug, ...

Imran Malik Publicity is marking its 10th anniversary with a key appointment. Publicist Katerina Marka is the agency’s new ...

This article summarizes the top insider buys and sells for US stocks reported on Friday, March 28, 2025. Top Insider Buys: ...

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $111.88, a 25.38% upside from current levels. In a report released on March 28, Leerink Partners also ...